SEARCH

SEARCH BY CITATION

References

  • 1
    Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311318.
  • 2
    Paraaskevas S, Kandaswamy R, Humar A et al.. Predicting long-term kidney graft survival: can new trials be performed Transplantation 2003; 75: 12561259.
  • 3
    Isoniemi H, Taskinen E, Häyry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994; 58: 11951198.
  • 4
    Yilmaz S, Tomlanovich S, Mathew T et al. Protocol core needle biopsy and histologic chronic allograft damage index (CADI) as surrogate end point for long-term graft survival in multicenter studies. J Am Soc Nephrol 2003; 14: 773779.
  • 5
    De Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kid Dis 2000; 35: 333346.
  • 6
    Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931940.
  • 7
    Rascusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of allograft pathology. Kidney Int 1999; 55: 713723.
  • 8
    DiJoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53: 507513.
  • 9
    Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436442.
  • 10
    Kahan BD for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194202.
  • 11
    Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847858.
  • 12
    Johnson RWG, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777786.
  • 13
    Oberbauer R, Kreis H, Johnson RWG et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364370.
  • 14
    Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809817.
  • 15
    Yilmaz S, Nutley M, Taskinen E et al.. Chronic allograft damage index as a surrogate marker for chronic allograft rejection. In: TrullA, PriceC, DemersLM (eds): Biomarkers of Disease. Cambridge , UK : Cambridge University Press, 2002: 433441.
  • 16
    Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 16831689.
  • 17
    Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411422.
  • 18
    Legendre C, Thervet E, Skhiri H et al. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65: 15061509.
  • 19
    Solez K, Vincenti F, Filo RS, for The FK506 Kidney Transplant Study Group. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. Transplantation 1998; 66: 17361740.
  • 20
    Stallone G, Di Paolo S, Schena A et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003; 75: 9981003.
  • 21
    MacDonald AS for the Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2000; 71: 271280.
  • 22
    Flechner SM, Burke JT, Cook DJ et al. A randomized prospective trial of sirolimus vs cyclosporine in renal transplantation: renal function and histology at two years. Am J Transplant 2003; 3: 450.